IDEAYA Biosciences, Inc.

NasdaqGS:IDYA Stock Report

Market Cap: US$2.2b

IDEAYA Biosciences Valuation

Is IDYA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IDYA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$38.75
Fair Value
36.7% undervalued intrinsic discount
16
Number of Analysts

Below Fair Value: Insufficient data to calculate IDYA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IDYA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IDYA?

Key metric: As IDYA barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for IDYA. This is calculated by dividing IDYA's market cap by their current book value.
What is IDYA's PB Ratio?
PB Ratio2.2x
BookUS$959.65m
Market CapUS$2.16b

Price to Book Ratio vs Peers

How does IDYA's PB Ratio compare to its peers?

The above table shows the PB ratio for IDYA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.5x
VRDN Viridian Therapeutics
4.5x49.81%US$1.5b
XENE Xenon Pharmaceuticals
4.4x24.14%US$2.8b
CDTX Cidara Therapeutics
3.4x0.57%US$1.7b
DNLI Denali Therapeutics
1.9x27.68%US$2.1b
IDYA IDEAYA Biosciences
2.2x17.17%US$2.2b

Price-To-Book vs Peers: IDYA is good value based on its Price-To-Book Ratio (2.2x) compared to the peer average (3.5x).

Price to Book Ratio vs Industry

How does IDYA's PB Ratio compare vs other companies in the US Biotechs Industry?

50 CompaniesPrice / BookEstimated GrowthMarket Cap
NKTX Nkarta
0.4x1.69%US$139.92m
ZNTL Zentalis Pharmaceuticals
0.4x13.87%US$107.48m
MGX Metagenomi
0.3x-16.66%US$69.81m
ARTV Artiva Biotherapeutics
0.4x-9.92%US$62.29m
IDYA 2.2xIndustry Avg. 2.2xNo. of Companies66PB01.63.24.86.48+
50 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: IDYA is expensive based on its Price-To-Book Ratio (2.2x) compared to the US Biotechs industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is IDYA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IDYA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IDYA's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IDYA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$24.61
US$46.88
+90.47%
25.80%US$74.00US$27.00n/a16
Sep ’26US$24.55
US$46.43
+89.12%
29.17%US$72.00US$25.00n/a14
Aug ’26US$24.27
US$46.50
+91.59%
28.12%US$72.00US$25.00n/a14
Jul ’26US$21.12
US$51.08
+141.84%
19.56%US$66.00US$27.00n/a13
Jun ’26US$19.89
US$51.67
+159.76%
19.70%US$66.00US$27.00n/a12
May ’26US$20.47
US$52.25
+155.25%
19.30%US$65.00US$27.00n/a12
Apr ’26US$14.77
US$52.62
+256.23%
18.57%US$65.00US$27.00n/a13
Mar ’26US$20.57
US$52.71
+156.27%
18.37%US$65.00US$27.00n/a14
Feb ’26US$24.35
US$55.71
+128.81%
16.86%US$65.00US$27.00n/a14
Jan ’26US$25.70
US$55.79
+117.07%
16.76%US$65.00US$27.00n/a14
Dec ’25US$27.36
US$54.87
+100.54%
17.00%US$65.00US$27.00n/a15
Nov ’25US$28.60
US$56.71
+98.30%
12.53%US$66.00US$41.00n/a14
Oct ’25US$30.73
US$57.23
+86.24%
11.18%US$66.00US$48.00n/a13
Sep ’25US$39.50
US$57.08
+44.50%
10.77%US$66.00US$47.00US$24.5513
Aug ’25US$42.46
US$57.92
+36.42%
11.38%US$69.00US$46.00US$24.2713
Jul ’25US$35.92
US$54.45
+51.60%
10.25%US$65.00US$46.00US$21.1211
Jun ’25US$36.55
US$52.82
+44.51%
6.50%US$60.00US$46.00US$19.8911
May ’25US$41.18
US$53.36
+29.59%
5.67%US$60.00US$50.00US$20.4711
Apr ’25US$42.52
US$53.27
+25.29%
5.72%US$60.00US$50.00US$14.7711
Mar ’25US$46.22
US$51.10
+10.56%
8.37%US$57.00US$40.00US$20.5710
Feb ’25US$44.53
US$42.10
-5.46%
13.79%US$53.00US$35.00US$24.3510
Jan ’25US$35.58
US$38.40
+7.93%
6.51%US$43.00US$35.00US$25.7010
Dec ’24US$31.63
US$37.67
+19.09%
10.47%US$44.00US$30.00US$27.3612
Nov ’24US$28.89
US$36.67
+26.92%
9.60%US$43.00US$30.00US$28.6012
Oct ’24US$26.98
US$36.08
+33.74%
10.88%US$43.00US$30.00US$30.7312
Sep ’24US$29.77
US$35.08
+17.85%
10.88%US$42.00US$30.00US$39.5012
AnalystConsensusTarget
Consensus Narrative from 16 Analysts
US$46.88
Fair Value
47.7% undervalued intrinsic discount
16
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/15 23:34
End of Day Share Price 2025/09/15 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IDEAYA Biosciences, Inc. is covered by 32 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Peter LawsonBarclays
Zhiqiang ShuBerenberg